- Home
- OTLK vs RGS Comparison
OTLK vs RGS Comparison
Compare OTLK & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- RGS
- Stock Information
- Founded
- OTLK 2010
- RGS 1922
- Country
- OTLK United States
- RGS United States
- Employees
- OTLK N/A
- RGS N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- RGS Other Consumer Services
- Sector
- OTLK Health Care
- RGS Consumer Discretionary
- Exchange
- OTLK Nasdaq
- RGS Nasdaq
- Market Cap
- OTLK 38.7M
- RGS 44.6M
- IPO Year
- OTLK 2016
- RGS 1991
- Fundamental
- Price
- OTLK $1.20
- RGS $17.82
- Analyst Decision
- OTLK Strong Buy
- RGS
- Analyst Count
- OTLK 5
- RGS 0
- Target Price
- OTLK $10.20
- RGS N/A
- AVG Volume (30 Days)
- OTLK 374.0K
- RGS 17.7K
- Earning Date
- OTLK 05-14-2025
- RGS 04-30-2025
- Dividend Yield
- OTLK N/A
- RGS N/A
- EPS Growth
- OTLK N/A
- RGS N/A
- EPS
- OTLK N/A
- RGS 40.46
- Revenue
- OTLK N/A
- RGS $191,336,000.00
- Revenue This Year
- OTLK N/A
- RGS N/A
- Revenue Next Year
- OTLK $288.46
- RGS N/A
- P/E Ratio
- OTLK N/A
- RGS $0.48
- Revenue Growth
- OTLK N/A
- RGS N/A
- 52 Week Low
- OTLK $0.87
- RGS $3.87
- 52 Week High
- OTLK $9.98
- RGS $35.50
- Technical
- Relative Strength Index (RSI)
- OTLK 34.06
- RGS 41.66
- Support Level
- OTLK $1.15
- RGS $16.83
- Resistance Level
- OTLK $1.31
- RGS $19.23
- Average True Range (ATR)
- OTLK 0.12
- RGS 1.06
- MACD
- OTLK -0.01
- RGS 0.14
- Stochastic Oscillator
- OTLK 20.45
- RGS 46.16
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RGS Regis Corporation
Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.